Akebia Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. The stock has a 50-day simple moving average of $2.90 and a 200 day simple moving average of $8.76. This company can help you start investing in this highly valuable asset class. PNC Financial Services Group Inc. bought a new position in Akebia Therapeutics in the 2nd quarter valued at $28,000. Get a free AKBA technical analysis report to make a better AKBA stock predictions on how the stock will perform in the near future. BTIG Research cut their price target on Akebia Therapeutics from $26.00 to $6.00 and set a "buy" rating for the company in a report on Friday, September 4th. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). The firm set an "overweight" rating and a $8.00 price target on the biopharmaceutical company's stock. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On further gains, the stock will meet resistance from the long-term moving average at $3.90. HC Wainwright is very positive to AKBA and gave it a "Buy" rating on March 08, 2021. Scan for strong stocks. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more. What Is Insider Buying? Akebia Therapeutics finds support from accumulated volume at $3.47 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Should I buy Akebia Therapeutics, Inc. (AKBA)? Looking for new stock ideas? Learn more. About the Akebia Therapeutics, Inc. stock forecast. But whether you’re facing a decision on where to allocate IRA contributions or just looking to spend some time this holiday season rebalancing your portfolio, you may be wondering what stocks to buy in January of next year. Our recommended stop-loss: What should you do? Specifically, 8 analysts have assigned AKBA a recommendation rating as follows: 1 rate it as a Hold; 6 advise Buy while none analyst(s) assign an Outperform rating. Please send any questions or comments about this story to [email protected]. Akebia Therapeutics Inc (AKBA) stock is trading at $2.79 as of 9:44 AM on Friday, Sep 4, an increase of $0.13, or 5.09% from the previous closing price of $2.65. Real-time data provided for free by IEX. Never miss a profitable trade. Zacks Investment Research reaffirmed a "buy" rating and issued a $6.00 price target (down previously from $17.00) on shares of Akebia Therapeutics in a report on Friday, September 4th. Akebia Therapeutics had a negative return on equity of 55.64% and a negative net margin of 113.35%. This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. Barchart Opinions are not a recommendation to buy or sell a security. For the last week, the stock has had a daily average volatility of 5.68%. The predicted opening price is based on yesterday's movements between high, low, and the closing price. NASDAQ AKBA opened at $2.42 on Wednesday. The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. View which stocks are hot on social media with MarketBeat's trending stocks report. Free Signup: View our full suite of financial calendars and market data tables, all for free. You can opt out at any time. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. Further fall is indicated until a new bottom pivot has been found. Eric Enderson - November 19, 2020. Mizuho cut their price target on Akebia Therapeutics from $17.00 to $6.00 and set a "buy" rating for the company in a report on Friday, September 4th. Find out now with a free analysis on Akebia Therapeutics. Please read the full disclaimer here. And in between, it wasn’t a whole lot calmer. AKBA has been the subject of several other research reports. To see all exchange delays and terms of use please see disclaimer. Institutional investors and hedge funds own 76.75% of the company's stock. The Akebia Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Akebia Therapeutics Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. Users should not base their investment decision upon "StockInvest.us". On a fall, the stock will find some support from the short-term average at $3.50. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.” Learn more. Akebia Therapeutics Accounts Payable Turnover is projected to increase significantly based on the last few years of reporting. AKBA Buy or Sell? Learn everything you need to know about successful options trading with this three-part video course. What's Happening With Akebia Therapeutics Inc Stock Today? "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). 5 of the analysts rate the stock as a “Buy”. Do Not Sell My Information. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
Wayne Couzens Bbc, Wow Private Server Solo Everything, Black Neighborhoods In Atlanta, Nba Schedule Release Date, Open Fm Radio App, Stubhub Arkansas Basketball, Uncle Murda Rap Up 2020' Sample,